Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06293625 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More

Study acronym: FOxTROT2France
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 7 wordsv4 See this version in full on ClinicalTrials.gov ↗
  2. Eligibility criteria shortened, about 11 wordsv3 See this version in full on ClinicalTrials.gov ↗
  3. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Mar 2032 to Jun 2032 · Start date changed from estimate of Mar 2024 to Jun 7, 2024 · Site details revisedv2 Show 3 more changesShow less
    • Primary and study completion dates: Mar 2032 to Jun 2032
    • Start date changed from estimate of Mar 2024 to Jun 7, 2024
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Colon cancer (CC) is the 5th most common cancer worldwide. Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy (AC) with oxaliplatin and 5-fluorouracil (OxFp). Almost all of these patients undergo surgery, but many do not receive AC due to frailty (following surgery). This particularly affects patients over 70, who represent the majority of patients diagnosed with CC. FOxTROT 2, a trial to test the role of NAC in older patients.
Trial Details
NCT Number NCT06293625
Lead Sponsor Centre Hospitalier Universitaire Dijon
Conditions Colon Cancer
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov